come on Tom 80 cents is long gone mate!
mind you.... one argument is if ARX is worth 250 million market cap on 6 products and 36 million revenue (and have been around longer) whats PNV worth at 44 million revenue (20% more)
it would suggest either one stock is too cheap pr another too expensive or there is other considerations at play
i think ARX looks seriously under valued and should be with 80% yoy growth and in healthcare space have at least a 10x revenue valuation of 360 million
Novosorb is able to achieve 44 million off less people newer patented product has more us GPOs signed then ARX .
come on Tom 80 cents is long gone mate! mind you.... one...
-
- There are more pages in this discussion • 4,100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
0.150(6.61%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.42 | $2.29 | $4.630M | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3536 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 38315 | 8 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |